The U.S. had 38 confirmed coronavirus deaths and 1,300 cases nationwide on March 11, 2020.
But reality was starting to sink in: stocks tanked, classrooms started closing, people began purchasing and wearing masks.
https://t.co/4cOPifmhlZ— The Associated Press (@AP) March 11, 2022
Since then, more than 6 million people have died globally.
Millions more have been infected and recovered. People have been thrown out of work, students have endured three school years of disruptions.@AP photos show how life was changed: https://t.co/Q3JZbS8VM7 pic.twitter.com/6ZKXJ3Fyxj
— The Associated Press (@AP) March 11, 2022
======
I've said it many times before, and I'll say it again: Whenever the pundits start referring to the #COVID19 #pandemic in the past tense, and pontificating about life after #SARSCoV2 , it's time to start bracing for the next surge. https://t.co/WqDM3v3iHa
— Laurie Garrett (@Laurie_Garrett) March 11, 2022
Asia passed the grim milestone of 1 million coronavirus-linked deaths on Friday, a Reuters tally showed, as a spike in Omicron variant infections spreads across the region after starting in nations such as Japan and South Korea. https://t.co/akL9O1NjE0
— Reuters Health (@Reuters_Health) March 11, 2022
It feels like I’m picking on China, but: The current situation is a big, important change of state!
China daily local COVID cases hit two-year high of over 1,500 https://t.co/tMLvS5FUhK pic.twitter.com/o9oeWSLnK2
— Reuters (@Reuters) March 12, 2022
… China’s current case count is far fewer than those of many other countries, but the growing number could complicate Beijing’s “dynamic-clearance” ambition to suppress contagion as quickly as possible.
The National Health Commission on Saturday said it had found 476 locally transmitted cases for Friday, including five people initially classified as asymptomatic who developed symptoms later.
There were 1,048 domestically transmitted asymptomatic infections, which China does not classify as confirmed cases, up from 703 a day earlier.
Beijing has ordered its localities to stick to the “dynamic clearing” policy and to prevent a large-scale rebound, prompting several cities to take measures such as cancelling group events, launching rounds of mass testing and cutting face-to-face classes in school.
At the same time the country is tweaking its testing regime in response to the spread of the Omicron variant, after having in the past two years required medical workers to swab members of the public using nucleic acid tests that require labs to process samples…
The northeastern province of Jilin said on Saturday it had dismissed the mayor of Jilin city and a district head in the capital, Changchun. The province has been one of the hardest-hit regions in the latest outbreak.
Changchun has ordered all but essential businesses to halt operations and banned its 9 million residents from leaving their residential compounds for non-essential reasons. Similar measures have been applied in urban areas of Jilin city.
Scene of mass PCR testing in Chongqing after 3 cases were confirmed in the city. pic.twitter.com/nyh1Do0MyR
— Yanzhong Huang (@YanzhongHuang) March 12, 2022
China approves five COVID-19 antigen kits for self-testing – CCTV https://t.co/WXMyAelluu pic.twitter.com/iv0lf0bnei
— Reuters (@Reuters) March 12, 2022
It's all kicking off in Shanghai today. Lockdowns everywhere. Someone's service apartment in Xujiahui commandeered by local authorities for anti-covid measures. Occupant was given two hours to move out. pic.twitter.com/h0SOSKAn8h
— Cameron Wilson 韦侃仑 (@CameronWEF) March 11, 2022
Hong Kong leader says city is not yet past COVID peak https://t.co/i4TPdQ7aNt pic.twitter.com/vmK4E14Lfh
— Reuters (@Reuters) March 12, 2022
This image will be forever burned into the back of Hong Kongers’ minds.
City leaders had two years to prepare for the inevitable day when the virus would breakthrough, two years to build capacity in hospitals, morgues, care homes etc – and a year to vaccinate the vulnerable. https://t.co/JcWeZ8jFE9
— Jerome Taylor (@JeromeTaylor) March 11, 2022
Hong Kong reported 27,647 Covid-19 infections on Saturday, of which 11,858 were from rapid tests.
Full, trusted coverage on HKFP: https://t.co/w8LTgNgHXy
Covid data explainer: https://t.co/5l83n2Y37W pic.twitter.com/HHMafhS5b7— Hong Kong Free Press HKFP (@hkfp) March 12, 2022
Hong Kong health authorities reported 29,381 new COVID-19 infections on Friday, of which 10,493 were confirmed via a self-reporting platform where people can register positive results of rapid antigen tests. https://t.co/ewf78sFvFY
— Reuters Health (@Reuters_Health) March 11, 2022
Hong Kong's COVID-19 vaccination program will focus on its elderly and children, leader Carrie Lam said, as authorities battled to reduce a surge of infections and climbing death rates https://t.co/QUf6sfLMcy pic.twitter.com/BcenDOACqI
— Reuters (@Reuters) March 12, 2022
Coronavirus Live: India Records Over 4,000 New Covid Cases In 24 Hours https://t.co/qnH3mRh9tC pic.twitter.com/HLGoPECRlO
— NDTV News feed (@ndtvfeed) March 12, 2022
South Korea reports record high 383,665 new COVID-19 cases – KDCA https://t.co/Er5XKmcti6 pic.twitter.com/Kmw8XHmClA
— Reuters (@Reuters) March 12, 2022
Covid infections rising again across UK, says Office for National Statistics https://t.co/HRUMNExZHy
— BBC News (World) (@BBCWorld) March 11, 2022
It’s weird, we dropped all restrictions and told people they no longer legally have to self-isolate if they have Covid and now cases are on the rise??? pic.twitter.com/2ZBxkK4J1Y
— James Felton (@JimMFelton) March 11, 2022
======
‘Stealth’ #omicron is stealthy no longer: Here is what’s known about the BA.2 subvariant: It's not yet causing a new surge in the United States and probably won’t https://t.co/xEhKb8nJ4G
— delthia ricks ? (@DelthiaRicks) March 12, 2022
Antivirals & certain monoclonal antibodies—mABs— work well against BA.2, #omicron's subvariant. Evusheld is an effective mAB that neutralizes it. But the mABs known as etesevimab & bamlanivmab—often used as a combo treatment—can't neutralize the subvariant https://t.co/SHumCXV4Gt
— delthia ricks ? (@DelthiaRicks) March 11, 2022
Continuing face mask use can save billions of dollars in the US. Maintaining face mask beyond the 70% to 90% fully vaccinated threshold can prevent a substantial number of new cases, hospitalizations & deaths. NY research. https://t.co/Y8xRGL1OAu via @medical_xpress
— delthia ricks ? (@DelthiaRicks) March 12, 2022
GeoVax vaccine targeting virus in two places shows promise; virus may become resistant to antibody drugs https://t.co/DMZIhx7HCD pic.twitter.com/qO1uyteVK3
— Reuters (@Reuters) March 12, 2022
… Like currently available COVID-19 vaccines, GeoVax’s GEO-CM04S1 induces immune responses that target the spike protein on the surface of the virus. But it also targets the “nucleocapsid,” or body, of the virus. In the study reported on Wednesday in The Lancet Microbe, 56 volunteers received the vaccine, which uses a modified version of a harmless virus to deliver instructions to the immune system. Overall, 94% developed antibodies against the spike and the nucleocapsid protein, according to the research team from City of Hope National Medical Center in Duarte, California. Other components of the immune system also responded well, including T cells, which protect against severe infection.
Two mid-stage trials of the vaccine are now underway. One is testing its safety and effectiveness in immunosuppressed patients with blood cancer. The other is testing it as a booster in healthy adults who previously received vaccines from Moderna (MRNA.O), Pfizer (PFE.N)/BioNTech or Johnson & Johnson (JNJ.N). The studies will look at the level of antibodies that can neutralize the Omicron variant, the researchers said…
Virus may become resistant, mutate after antibody treatment
COVID-19 patients who receive one of the few antibody treatments that works against the Omicron variant must be carefully monitored because after the drug is infused, the virus may mutate and become resistant to it, researchers warned after seeing such cases with Delta variant patients.They studied 100 patients infected with the Delta variant who were treated with an intravenous dose of sotrovimab from GlaxoSmithKline (GSK.L) and Vir Biotechnology (VIR.O). Eight of the patients continued to shed infectious virus for longer than doctors expected, and tests showed that four of the eight had virus particles with mutations that are known to reduce the drug’s effectiveness. The mutations had developed within six to 13 days after the patients started receiving the drug, the research team reported in The New England Journal of Medicine on Wednesday. The same mutations were seen in four of 45 participants in an earlier clinical trial of the drug, said Rebecca Rockett of the University of Sydney, Australia, the report’s lead author…
======
How to not be prepared. Again.https://t.co/YOPzEJ04uB @ddiamond @TonyRomm pic.twitter.com/IGeuY98yA3
— Eric Topol (@EricTopol) March 11, 2022
Free tip for anyone covering protests against covid-19 mandates:
If you find you somehow neglected to include any actual examples of mandates in the story you just wrote about mandates, it's probably because there are basically no mandates. Stop gaslighting your readers. https://t.co/83tK2YlPjO
— dell cameron (@dellcam) March 11, 2022
COVID-19 Coronavirus Updates: Friday / Saturday, March 11-12Post + Comments (36)